Anatomic Pathology, Tor Vergata University, Rome, Italy.
Sigma-Tau, Pomezia, Rome, Italy.
Clin Transl Gastroenterol. 2014 Mar 20;5(3):e55. doi: 10.1038/ctg.2014.4.
Microvascular endothelial dysfunction characterizes ulcerative colitis (UC), the most widespread form of inflammatory bowel disease. Intestinal mucosal microvessels in UC display aberrant expression of cell adhesion molecules (CAMs) and increased inflammatory cell recruitment. Propionyl-L-carnitine (PLC), an ester of L-carnitine required for the mitochondrial transport of fatty acids, ameliorates propionyl-CoA bioavailability and reduces oxidative stress in ischemic tissues. The present study aimed to document the efficacy of anti-oxidative stress properties of PLC in counteracting intestinal microvascular endothelial dysfunction and inflammation.
To evaluate the efficacy in vivo, we analyzed the effects in intestinal biopsies of patients with mild-to-moderate UC receiving oral PLC co-treatment and in rat TNBS-induced colitis; in addition, we investigated antioxidant PLC action in TNF-α-stimulated human intestinal microvascular endothelial cells (HIMECs) in vitro.
Four-week PLC co-treatment reduced intestinal mucosal polymorph infiltration and CD4(+) lymphocytes, ICAM-1(+) and iNOS(+) microvessels compared with placebo-treated patients with UC. Oral and intrarectal administration of PLC but not L-carnitine or propionate reduced intestinal damage and microvascular dysfunction in rat TNBS-induced acute and reactivated colitis. In cultured TNF-α-stimulated HIMECs, PLC restored β-oxidation and counteracted NADPH oxidase 4-generated oxidative stress-induced CAM expression and leukocyte adhesion. Inhibition of β-oxidation by L-aminocarnitine increased reactive oxygen species production and PLC beneficial effects on endothelial dysfunction and leukocyte adhesion. Finally, PLC reduced iNOS activity and nitric oxide accumulation in rat TNBS-induced colitis and in HIMEC cultures.
Our results show that the beneficial antioxidant effect of PLC targeting intestinal microvasculature restores endothelial β-oxidation and function, and reduces mucosal inflammation in UC patients.
微血管内皮功能障碍是溃疡性结肠炎(UC)的特征,UC 是炎症性肠病中最常见的形式。UC 患者的肠道黏膜微血管显示细胞黏附分子(CAMs)异常表达和炎症细胞募集增加。丙酰基-L-肉碱(PLC)是脂肪酸线粒体转运所必需的肉碱酯,可改善丙酰辅酶 A 的生物利用度并减少缺血组织的氧化应激。本研究旨在记录 PLC 的抗氧化应激特性在对抗肠道微血管内皮功能障碍和炎症中的功效。
为了评估体内的疗效,我们分析了轻度至中度 UC 患者接受口服 PLC 联合治疗的肠道活检标本的效果,以及在大鼠 TNBS 诱导的结肠炎中的效果;此外,我们还研究了 PLC 在 TNF-α刺激的人肠道微血管内皮细胞(HIMEC)中的抗氧化作用。
与接受 UC 安慰剂治疗的患者相比,为期 4 周的 PLC 联合治疗可减少肠道黏膜多形核白细胞浸润和 CD4+淋巴细胞、ICAM-1+和 iNOS+微血管。与 L-肉碱或丙酸盐相比,口服和直肠内给予 PLC 可减少大鼠 TNBS 诱导的急性和再激活结肠炎中的肠道损伤和微血管功能障碍。在 TNF-α刺激的 HIMEC 培养物中,PLC 恢复了β-氧化,并对抗 NADPH 氧化酶 4 产生的氧化应激诱导的 CAM 表达和白细胞黏附。L-氨基肉碱抑制β-氧化会增加活性氧的产生,并增强 PLC 对内皮功能障碍和白细胞黏附的有益作用。最后,PLC 减少了大鼠 TNBS 诱导的结肠炎和 HIMEC 培养物中的 iNOS 活性和一氧化氮积累。
我们的研究结果表明,PLC 针对肠道微血管的有益抗氧化作用可恢复内皮细胞的β-氧化和功能,并减轻 UC 患者的黏膜炎症。